X-linked lymphoproliferative disease (XLP) is characterized by a selective immune deficiency to EBV. The molecular basis of XLP has been attributed to mutations of signaling lymphocytic activation molecule-associated protein, an intracellular molecule known to associate with the lymphocyte-activating surface receptors SLAM and 2B4. We have identified a single nucleotide mutation in SLAM-associated protein that affects the NK cell function of males carrying the mutated gene. In contrast to normal controls, both NK and lymphokine-activated killer cell cytotoxicity was significantly reduced in two XLP patients. In addition to decreased baseline cytotoxicity, ligation of 2B4 significantly augmented NK lytic function in normal controls but failed to enhance the cytotoxicity of NK cells from XLP patients. These findings suggest that association of SAP with 2B4 is necessary for optimal NK/lymphokine-activated killer cytotoxicity and imply that alterations in SAP/2B4 signaling contribute to the immune dysfunction observed in XLP.

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.165.7.3549DOI Listing

Publication Analysis

Top Keywords

x-linked lymphoproliferative
8
lymphoproliferative disease
8
normal controls
8
xlp patients
8
xlp
5
defective cell
4
cell activation
4
activation x-linked
4
disease x-linked
4
disease xlp
4

Similar Publications

X-linked lymphoproliferative disease (XLP) is a rare primary immunodeficiency with susceptibility and vulnerability to Epstein-Barr virus (EBV) infection. Most patients were diagnosed in early childhood and do not survive into adulthood. Here we reported an adult-onset XLP patient presenting with fever, dyspnea, and pulmonary nodules, mimicking respiratory infection at disease onset.

View Article and Find Full Text PDF
Article Synopsis
  • Wiskott-Aldrich syndrome (WAS) is a rare genetic disorder that affects mostly boys and causes issues like eczema, low platelet counts, and a weak immune system.
  • A 7-month-old baby showed symptoms like slow growth, mild eczema, and frequent colds, but his platelet levels kept dropping even with treatment.
  • Finally, genetic tests confirmed he had WAS, which is linked to a mutation on the X chromosome.
View Article and Find Full Text PDF

Lentiviral vectors for precise expression to treat X-linked lymphoproliferative disease.

Mol Ther Methods Clin Dev

December 2024

Department of Molecular & Medical Pharmacology, University of California, Los Angeles, Los Angeles, CA 90095, USA.

X-linked lymphoproliferative disease (XLP1) results from gene mutations affecting the SLAM-associated protein (SAP). A regulated lentiviral vector (LV), XLP-SMART LV, designed to express SAP at therapeutic levels in T, NK, and NKT cells, is crucial for effective gene therapy. We experimentally identified 34 genomic regulatory elements of the gene and designed XLP-SMART LVs to emulate the lineage and stage-specific control of SAP.

View Article and Find Full Text PDF

The aim of this study was to investigate the prognostic factors of haploid hematopoietic stem cell transplantation in the treatment of X-linked lymphoproliferative syndrome. Seven children with X-linked lymphoproliferative syndrome diagnosed by XIAP gene analysis were enrolled. The conditioning regimens were tolerated in all seven patients, and the median time of neutrophil engraftment was 10 days (8-13 days), and that of platelet engraftment was 21 days (14-24 days).

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!